BDTX

AI Memo

Black Diamond Therapeutics

As of 2026-08-17/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Q4 2026 NSCLC update and FDA pivotal-path feedback • 2026-12-31

Base target: $2 / p=50% prob

Biggest risk

The clinical evidence remains preliminary and based on a relatively small Phase 2 population. FDA feedback may not support a pivotal path, future trial results may not replicate current activity, and the GBM program adds execution and development risk. No analyst revisions or target changes are available.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Silevertinib has encouraging preliminary activity in non-classical EGFR-mutant NSCLC, including CNS responses, no reported de novo brain metastases, and a potential Q4 FDA pivotal-path update [#SEC-8K-2026-08-05]. The extended runway supports continued development without immediate financing dependence.

Research note

Recommendation

—

Confidence

medium

As of

2026-08-17

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

GBM randomized Phase 2 advancement
Cash runway reduces near-term financing pressure
Silevertinib has encouraging preliminary activity in non-classical EGFR-mutant NSCLC, including CNS responses, no reported de novo brain metastases, and a potential Q4 FDA pivotal-path update [#SEC-8K-2026-08-05].

BearKey bullets

Cash declined from $128.7 million at year-end 2025 to $110.5 million at June 30, 2026; additional financing could eventually be required despite the stated runway [#SEC-8K-2026-08-05].
Low coverage and loose peers limit confidence in valuation and market-expectation assessment.
Preliminary Phase 2 data may not translate into confirmatory efficacy or regulatory success.

WatchKey bullets

Q4 2026 NSCLC update and FDA pivotal-path feedback

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +23% / -36%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $2 (p=50%)Bear Target: $1 (p=25%)

Commentary

The latest company update was clinically constructive, while the stored Associated Press earnings snapshot reported a $0.17 per-share loss versus a $0.18 estimate [#PR-EARNINGS-2026-08-05]. The stock remains a low-coverage, event-driven biotech situation; analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable, so confidence is limited.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

GBM randomized Phase 2 advancement
Cash runway reduces near-term financing pressure

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

60.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
Q4 2026 NSCLC update and FDA pivotal-path feedback
Black Diamond expects to provide a Q4 2026 update on the silevertinib Phase 2 frontline non-classical EGFR-mutant NSCLC trial and FDA feedback on a potential pivotal development path. Reported Phase 2 metrics included 60% ORR, 86% CNS ORR, 91% DCR, and preliminary median PFS of 15.2 months [#SEC-8K-2026-08-05].
Prob 65.00% • Move 35.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

GBM randomized Phase 2 advancement
2026-12-31
The silevertinib-plus-temozolomide Phase 2 study in newly diagnosed EGFRvIII-positive glioblastoma is enrolling its safety lead-in, with the randomized portion expected to begin in Q4 2026 [#SEC-8K-2026-08-05].
Prob 55% • Move 20% • Priced-in 30%
Cash runway reduces near-term financing pressure
2028-06-30
Cash, cash equivalents, and investments were $110.5 million as of June 30, 2026, and the company expects funding to support operations into the second half of 2028 [#SEC-SEC-8K-2026-08-05].
Prob 75% • Move 5% • Priced-in 70%

Risks

Cash declined from $128.7 million at year-end 2025 to $110.5 million at June 30, 2026; additional financing could eventually be required despite the stated runway [#SEC-8K-2026-08-05].
Low coverage and loose peers limit confidence in valuation and market-expectation assessment.
Preliminary Phase 2 data may not translate into confirmatory efficacy or regulatory success.
Q4 FDA feedback could delay, narrow, or reject a pivotal development path for silevertinib.
The GBM program is early-stage and its randomized Phase 2 launch may face enrollment, safety, or execution setbacks.

Peers

Symbol	Summary
CPIX	Similarly sized same-sector company; useful for small-cap biotechnology risk context but not a direct therapeutic peer.
ENGN	Similarly sized same-sector biotechnology comparator with limited direct product overlap.
NAUT	Similarly sized same-sector biotechnology comparator, relevant mainly for clinical-stage and financing-risk context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

CPIX

Similarly sized same-sector company; useful for small-cap biotechnology risk context but not a direct therapeutic peer.

ENGN

Similarly sized same-sector biotechnology comparator with limited direct product overlap.

NAUT

Similarly sized same-sector biotechnology comparator, relevant mainly for clinical-stage and financing-risk context.